Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Studies from Case Western Reserve University have provided new information about breast cancer
May 15th, 2008
According to recent research from the United States, " Five years of adjuvant tamoxifen therapy for estrogen receptor ( ER)-positive breast cancer is more effective than 2 years of use. However, information on tamoxifen discontinuation is scanty." "We sought to identify predictors of tamoxifen discontinuation among older women with breast cancer. Patients and Methods Within six health care delivery systems, we identified women >= 65 years old diagnosed with stage I to IIB ER-positive or indeterminant breast cancer between 1990 and 1994 who had filled a prescription for adjuvant tamoxifen. We observed them for 5 years after initial tamoxifen prescription. We used...
Source: Women's Health Weekly (2008-05-15)
|
